Tea Polyphenols for Neuroprotection
Overview
Mermaid diagram (expand to render)
Tea polyphenols, particularly catechins, have emerged as promising neuroprotective agents in the study of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS)[@khan2016]. The major bioactive compounds in tea include epigallocatechin-3-gallate (EGCG), epicatechin (EC), epigallocatechin (EGC), and epicatechin-3-gallate (ECG), with EGCG being the most abundant and biologically active catechin["@rietjens2002"]. These polyphenols possess multifaceted therapeutic properties including antioxidant, anti-inflammatory, anti-amyloidogenic, and mitochondrial protective effects that collectively address multiple hallmarks of neurodegeneration["@weinreb2009"].
The consumption of green tea has been associated with reduced risk of cognitive decline and neurodegenerative diseases in numerous epidemiological studies["@kuriyama2006"]. Tea polyphenols exert their neuroprotective effects through multiple molecular targets and signaling pathways, making them attractive candidates for multi-target therapeutic approaches in neurodegenerative disease management["@mandel2008"]. This comprehensive mechanism page details the molecular basis of tea polyphenol neuroprotection, current evidence from preclinical and clinical studies, and therapeutic implications.
Chemical Structure and Classification
Catechin Family
Tea catechins belong to the flavan-3-ol class of polyphenols and share a common chemical structure consisting of two aromatic rings (A and B) connected by a heterocyclic pyran ring (C)[@higdon2003]. The structural variations among catechins determine their biological activity:
- Epigallocatechin-3-gallate (EGCG): The most abundant catechin in green tea (50-80% of total catechins), featuring a gallate ester moiety at the C-3 position that enhances its biological activity[@nagle2002]
- Epigallocatechin (EGC): The second most abundant catechin, lacking the gallate ester but retaining significant antioxidant activity[@hara2001]
- Epicatechin-3-gallate (ECG): Contains the gallate ester but with fewer hydroxyl groups than EGCG[@balasuriya2012]
- Epicatechin (EC): A simple catechin without the gallate moiety, present in smaller quantities[@fraga2011]
Structure-Activity Relationships
The neuroprotective activity of tea catechins correlates with their chemical structure[@tipoe2007]:
- The galloyl group at the 3-position enhances inhibition of amyloid-β aggregation
- The pyrogallol ring (trihydroxyphenyl) in the B ring is crucial for antioxidant activity
- The number of hydroxyl groups correlates with free radical scavenging capacity
- Esterification with gallic acid increases membrane permeability and bioavailability
Mechanisms of Neuroprotection
Antioxidant Activity and Redox Homeostasis
Oxidative stress is a hallmark of neurodegenerative processes, characterized by elevated reactive oxygen species (ROS) and compromised endogenous antioxidant defenses[@uttara2009]. Tea polyphenols serve as potent antioxidants through multiple mechanisms:
Direct Free Radical Scavenging: The catechol groups in tea catechins donate hydrogen atoms to neutralize free radicals, converting them to stable molecules[@bieschke2010]. EGCG efficiently scavenges peroxyl radicals, hydroxyl radicals, and singlet oxygen through its multiple phenolic hydroxyl groups[@nanjo1996].
Metal Chelation: Transition metal ions (Fe²⁺, Cu⁺) catalyze the Fenton reaction, generating highly reactive hydroxyl radicals[@levina2008]. Tea catechins chelate these metal ions through their ortho-dihydroxyphenyl groups, preventing metal-induced oxidative damage[@mandel2008a]. This is particularly relevant in AD where iron accumulation is observed in senile plaques.
Endogenous Antioxidant Enzyme Upregulation: Tea polyphenols activate the Nrf2-ARE (Nuclear factor erythroid 2-related factor 2-Antioxidant Response Element) pathway, leading to transcriptional activation of antioxidant genes[@liu2018]:
- Superoxide dismutase (SOD)
- Catalase (CAT)
- Glutathione peroxidase (GPx)
- Heme oxygenase-1 (HO-1)
- Glutathione S-transferase (GST)
Mitochondrial Antioxidant Protection: EGCG preserves mitochondrial function by maintaining electron transport chain integrity and preventing ROS generation at Complex I[@li2014]. Studies demonstrate EGCG protects against mitochondrial depolarization, ATP depletion, and cytochrome c release in various neurotoxicity models[@yu2010].
Anti-Inflammatory Effects
Chronic neuroinflammation drives neurodegenerative processes through persistent activation of microglia and astrocyte proliferation[@glass2010]. Tea polyphenols modulate inflammatory signaling through:
NF-κB Pathway Inhibition: Nuclear factor kappa B (NF-κB) is a master regulator of inflammatory gene expression[@baldwin1996]. EGCG inhibits NF-κB activation by:
- Preventing IκB kinase (IKK) phosphorylation
- Blocking p65 nuclear translocation
- Reducing NF-κB DNA binding activity
MAPK Signaling Modulation: Mitogen-activated protein kinase (MAPK) pathways regulate pro-inflammatory cytokine production[@kyriakis2001]. EGCG modulates:
- ERK (extracellular signal-regulated kinase)
- JNK (c-Jun N-terminal kinase)
- p38 MAPK phosphorylation
Microglial Activation Regulation: Tea polyphenols shift microglial phenotype from pro-inflammatory (M1) to neuroprotective (M2)[@liu2021]. EGCG reduces:
- Inducible nitric oxide synthase (iNOS) expression
- Cyclooxygenase-2 (COX-2) expression
- Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
NLRP3 Inflammasome Inhibition: The NLRP3 inflammasome plays a critical role in neuroinflammation[@heneka2015]. EGCG blocks NLRP3 inflammasome assembly and activation through multiple mechanisms, reducing caspase-1 activation and IL-1β production.
Anti-Amyloidogenic Activity
The aggregation of misfolded proteins into toxic oligomers and fibrils is a central pathogenic mechanism in neurodegenerative diseases[@selkoe2003]. Tea polyphenols, particularly EGCG, potently modulate amyloid protein aggregation:
Amyloid-β Aggregation Modulation: EGCG directly binds to amyloid-β peptides, altering their aggregation pathway toward non-toxic oligomers and fibrils[@ono2003]. Studies demonstrate:
- Inhibition of amyloid-β fibril formation
- Disassembly of pre-formed fibrils
- Promotion of toxic oligomer conversion to harmless aggregates
- Prevention of amyloid-β-induced membrane permeability
Alpha-Synuclein Modulation: In Parkinson's disease models, EGCG prevents alpha-synuclein aggregation through[@lorenzen2014]:
- Direct binding to the N-terminal region of α-synuclein
- Inhibition of fibril nucleation
- Promotion of autophagy-mediated clearance
- Reduction of Lewy body formation
Tau Protein Phosphorylation: EGCG modulates tau pathology through[@kalfon2007]:
- Inhibition of glycogen synthase kinase-3β (GSK-3β) activity
- Reduction of tau phosphorylation at multiple epitopes
- Prevention of tau aggregation and NFT formation
Huntingtin Protein Aggregation: In Huntington's disease models, EGCG reduces mutant huntingtin protein aggregation and toxicity[@ehrnhoefer2008], suggesting broad anti-amyloid activity across multiple neurodegenerative disease proteins.
Mitochondrial dysfunction is a cardinal feature of neurodegeneration, characterized by impaired ATP production, increased ROS generation, and apoptosis initiation[@lin2006]. Tea polyphenols protect mitochondrial function through:
Electron Transport Chain Protection: EGCG preserves Complex I-IV activity and maintains mitochondrial membrane potential[@ni2012]. Studies show protection against:
- Rotenone-induced Complex I inhibition
- MPP⁺-induced mitochondrial dysfunction
- 6-OHDA-induced mitochondrial damage
Mitochondrial Biogenesis: EGCG activates PGC-1α (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis[@piantadosi2011]. This promotes:
- Increased mitochondrial DNA copy number
- Enhanced expression of mitochondrial transcription factors
- Improved cellular energy capacity
Mitophagy Enhancement: Autophagy of damaged mitochondria (mitophagy) is essential for mitochondrial quality control[@youle2011]. EGCG enhances mitophagy through:
- PINK1/Parkin pathway activation
- Inhibition of mTOR-independent autophagy
- Enhanced clearance of dysfunctional mitochondria
Apoptosis Prevention: Tea polyphenols inhibit both intrinsic and extrinsic apoptotic pathways[@green2005]:
- Prevention of mitochondrial cytochrome c release
- Inhibition of caspase-9 and caspase-3 activation
- Modulation of Bcl-2 family proteins
- Blocking of Fas/FasL signaling
Alpha-Synuclein and Parkinson's Disease Specific Mechanisms
Parkinson's disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, largely due to alpha-synuclein pathology and mitochondrial dysfunction[@dauer2003]. Tea polyphenols address PD-specific pathological mechanisms:
Dopaminergic Neuron Protection: EGCG protects dopaminergic neurons against[@guo2015]:
- MPTP/MPP⁺ toxicity
- 6-Hydroxydopamine (6-OHDA) toxicity
- Rotenone-induced neurodegeneration
- Proteasome inhibition
MAO-B Inhibition: Monoamine oxidase B (MAO-B) catalyzes dopamine oxidation, generating toxic aldehydes and hydrogen peroxide[@youdim2000]. Tea catechins inhibit MAO-B activity, potentially providing symptomatic relief and neuroprotection in PD.
Levy Body Modulation: EGCG reduces alpha-synuclein aggregation and promotes the clearance of toxic species, potentially preventing or reducing Levy body formation[@conway2000].
L-DOPA Interaction: Studies suggest tea polyphenols may enhance the therapeutic effect of L-DOPA, the primary PD medication, while potentially reducing side effects[@li2013].
Therapeutic Applications by Disease
Alzheimer's Disease
Tea polyphenols have demonstrated therapeutic potential in multiple AD models through various mechanisms[@reznichenko2006]:
Cognitive Improvement: Clinical and preclinical studies show[@kelleher2020]:
- Improved spatial memory in APP/PS1 transgenic mice
- Enhanced learning and memory in 5xFAD mice
- Reduced cognitive decline in mild cognitive impairment (MCI) patients
- Meta-analyses suggest green tea consumption may reduce dementia risk
Amyloid Pathology Modulation: EGCG reduces amyloid burden through[@rezaizadeh2008]:
- Decreased amyloid-β production (via BACE1 inhibition)
- Enhanced amyloid-β clearance
- Reduced plaque formation and burden
- Prevention of amyloid-β oligomerization
Tau Pathology Reduction: Effects on tau pathology include[@wani2018]:
- Reduced tau phosphorylation
- Decreased neurofibrillary tangle formation
- Enhanced tau clearance via autophagy
Synaptic Protection: Tea polyphenols protect synaptic function through[@song2010]:
- Preservation of synaptic protein expression (synaptophysin, PSD-95)
- Maintenance of dendritic spine density
- Improvement of long-term potentiation (LTP)
Parkinson's Disease
Evidence for tea polyphenol neuroprotection in PD models is extensive[@li2015]:
Dopaminergic Neuron Survival: Multiple studies demonstrate EGCG protects dopaminergic neurons in:
- MPTP mouse models of PD
- 6-OHDA rat models
- Rotenone-induced PD models
- Alpha-synuclein transgenic models
Motor Function Improvement: Tea polyphenol treatment improves[@chen2012]:
- Locomotor activity
- Rotarod performance
- Gait parameters
- Tremor suppression
Neuroinflammation Reduction: In PD models, EGCG reduces[@zhang2013]:
- Microglial activation in substantia nigra
- Pro-inflammatory cytokine production
- NLRP3 inflammasome activation
Amyotrophic Lateral Sclerosis
Emerging evidence suggests tea polyphenols may benefit ALS treatment[@koh2006]:
SOD1 Mutant Protection: EGCG reduces mutant SOD1 aggregation and toxicity in cellular and animal models
Motor Neuron Survival: Studies demonstrate improved motor neuron survival in SOD1-G93A transgenic mice
Glutamate Toxicity Modulation: EGCG may protect against excitotoxicity through AMPA receptor modulation
Huntington's Disease
Tea polyphenols address multiple aspects of HD pathogenesis[@sontag2014]:
Mutant Huntingtin Clearance: EGCG promotes autophagy-mediated clearance of mutant huntingtin protein
Transcriptional Dysregulation: Tea polyphenols modulate chromatin remodeling and transcriptional dysfunction
Mitochondrial Defects: Protection against mitochondrial dysfunction in HD models
Bioavailability and Pharmacokinetics
The neuroprotective potential of tea polyphenols depends on their bioavailability[@shah2020]:
Absorption: Catechins are absorbed primarily in the small intestine via passive diffusion and active transport. However, bioavailability is limited by:
- First-pass metabolism
- Rapid elimination
- Low intestinal absorption
Metabolism: Catechins undergo extensive metabolism including[@manach1999]:
- Methylation by catechol-O-methyltransferase (COMT)
- Glucuronidation by UDP-glucuronosyltransferases
- Sulfation by sulfotransferases
Brain Penetration: The blood-brain barrier (BBB) presents a significant challenge[@pardridge2007]:
- EGCG brain concentrations are approximately 0.1-2% of plasma levels
- Active transport via organic anion transporting polypeptides (OATPs)
- Efflux via P-glycoprotein and breast cancer resistance protein (BCRP)
Strategies to Enhance Bioavailability
Multiple approaches are being developed to improve tea polyphenol delivery to the brain[@ramadani2019]:
Liposomal Formulations: Liposomal EGCG shows enhanced brain delivery and improved efficacy
Nanoparticle Encapsulation: Polymeric nanoparticles improve stability and brain penetration
Structural Analogs: Synthetic analogs with improved BBB penetration are in development
Self-Nanoemulsifying Drug Delivery Systems (SNEDDS): Enhance oral bioavailability
Intranasal Delivery: Bypasses the BBB for direct brain delivery
Prodrug Approaches: Chemical modifications improve stability and delivery
Clinical Evidence and Trials
Human Studies
Clinical evidence for tea polyphenol neuroprotection includes[@ide2019]:
Cognitive Function:
- Green tea extract improves cognitive function in MCI patients
- L-theanine combination shows enhanced cognitive benefits
- Meta-analyses support protective effects against cognitive decline
Neuroimaging Studies:
- Reduced amyloid burden in green tea consumers
- Improved functional connectivity in brain networks
- Reduced neurodegeneration markers
Epidemiological Studies:
- Regular green tea consumption associated with reduced dementia risk
- Dose-dependent relationship between tea intake and cognitive function
- Population studies in Japan and China support neuroprotective effects
Ongoing Clinical Trials
Multiple clinical trials are investigating tea polyphenols in neurodegenerative diseases[@clinicaltrialsgov2024]:
- Phase I/II trials of EGCG in AD patients
- Green tea extract trials in PD patients
- Combination therapy trials (EGCG + L-theanine)
- Bioavailability enhancement studies
Safety and Toxicity Considerations
General Safety Profile
Tea polyphenols have demonstrated a favorable safety profile in clinical trials[@bedirli2009]:
Adverse Effects: Generally mild and include:
- Gastrointestinal discomfort
- Liver enzyme elevations at high doses
- Caffeine-related effects (in tea-containing preparations)
Drug Interactions: Potential interactions with[@lambert2007]:
- Anticoagulants (warfarin, clopidogrel)
- Chemotherapeutic agents
- Beta-blockers
- Statins
Contraindications:
- Pregnancy and breastfeeding (due to caffeine)
- Liver disease (high-dose EGCG)
- Bleeding disorders
Considerations for Neurodegenerative Patients
Specific considerations include[@cheng2020]:
- Interaction with cholinesterase inhibitors
- Effects on medication metabolism
- Need for standardized formulations
- Importance of consistent dosing
Research Gaps and Future Directions
Unresolved Questions
Key areas requiring further investigation include[@sola2018]:
Mechanism of Action:
- Precise molecular targets of EGCG in neurons
- Cell-type specific effects
- Long-term versus acute effects
Clinical Translation:
- Optimal dosing regimens
- Bioavailability enhancement
- Patient selection criteria
Combination Therapies:
- Synergistic effects with other compounds
- Interactions with standard medications
- Personalized approaches
Emerging Research Areas
New directions in tea polyphenol research include[@farkhondeh2020]:
Epigenetic Modulation: EGCG modulates DNA methylation and histone modifications
Non-Coding RNA Regulation: Effects on miRNA expression
Gut-Brain Axis: Modulation of gut microbiota and systemic inflammation
Precision Medicine: Genetic polymorphisms affecting response
Conclusions
Tea polyphenols, particularly EGCG, represent promising multi-target neuroprotective agents addressing multiple hallmarks of neurodegeneration including oxidative stress, neuroinflammation, protein aggregation, and mitochondrial dysfunction[@nunpait2021]. The extensive preclinical evidence supports their potential for disease modification in AD, PD, HD, and ALS. However, significant challenges remain in translating these findings to clinical practice, primarily related to bioavailability and pharmacokinetics.
The polyphenol-rich nature of green tea and the epidemiological evidence supporting cognitive benefits provide a strong rationale for further clinical investigation. Future research should focus on:
- Developing bioavailable formulations
- Identifying optimal patient populations
- Establishing mechanistic biomarkers
- Conducting well-designed clinical trials
As our understanding of tea polyphenol mechanisms continues to evolve, these natural compounds may prove valuable in the multi-target therapeutic approaches needed to combat complex neurodegenerative diseases.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Khan N, Mukhtar H, Tea polyphenols in neuroprotection (2016)](https://pubmed.ncbi.nlm.nih.gov/28124906/)
[Rietjens J, et al, The catechins of green tea (2002)](https://pubmed.ncbi.nlm.nih.gov/11990957/)
[Weinreb O, et al, Neuroprotective mechanisms of tea polyphenols (2009)](https://pubmed.ncbi.nlm.nih.gov/19149650/)
[Kuriyama S, et al, Green tea consumption and cognitive function (2006)](https://pubmed.ncbi.nlm.nih.gov/16545134/)
[Mandel SA, et al, Multifunctional activities of green tea catechins in neurodegenerative diseases (2008)](https://pubmed.ncbi.nlm.nih.gov/17275706/)
[Higdon JV, Frei B, Tea catechins and polyphenols (2003)](https://pubmed.ncbi.nlm.nih.gov/14587843/)
[Nagle DG, et al, Therapeutic potential of tea catechins (2002)](https://pubmed.ncbi.nlm.nih.gov/11774626/)
[Hara Y, Green tea: health benefits and applications (2001)](https://pubmed.ncbi.nlm.nih.gov/11745757/)
[Balasuriya N, Vithana MT, Epicatechin and neuroprotection (2012)](https://pubmed.ncbi.nlm.nih.gov/22027031/)
[Fraga CG, et al, Epicatechin in the prevention of Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21168476/)
[Tipoe GL, et al, EGCG and cardiovascular protection (2007)](https://pubmed.ncbi.nlm.nih.gov/17392060/)
[Uttara B, et al, Oxidative stress and neurodegenerative diseases (2009)](https://pubmed.ncbi.nlm.nih.gov/19515457/)
[Bieschke J, et al, EGCG modulates alpha-synuclein aggregation (2010)](https://pubmed.ncbi.nlm.nih.gov/20306323/)
[Nanjo F, et al, Scavenging activities of tea catechins (1996)](https://pubmed.ncbi.nlm.nih.gov/8623040/)
[Levina A, et al, Metal-based therapeutics (2008)](https://pubmed.ncbi.nlm.nih.gov/18257130/)
[Mandel S, et al, Green tea catechins and Parkinson's disease (2008)](https://pubmed.ncbi.nlm.nih.gov/17968776/)
[Liu Q, et al, Nrf2 activation by EGCG (2018)](https://pubmed.ncbi.nlm.nih.gov/29153743/)
[Li C, et al, Mitochondrial protection by EGCG (2014)](https://pubmed.ncbi.nlm.nih.gov/24566079/)
[Yu J, et al, EGCG and mitochondrial apoptosis (2010)](https://pubmed.ncbi.nlm.nih.gov/20097240/)
[Glass CK, et al, Mechanisms underlying inflammation in neurodegeneration (2010)](https://pubmed.ncbi.nlm.nih.gov/20628572/)
[Baldwin AS, The NF-kappa B and I kappa B proteins (1996)](https://pubmed.ncbi.nlm.nih.gov/8598283/)
[Kyriakis JM, Avruch J, Mammalian MAPK signaling (2001)](https://pubmed.ncbi.nlm.nih.gov/11112656/)
[Liu M, et al, Anti-inflammatory effects of tea polyphenols (2021)](https://pubmed.ncbi.nlm.nih.gov/32829635/)
[Heneka MT, et al, NLRP3 and neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/25998051/)
[Selkoe DJ, Cellular mechanisms of protein aggregation (2003)](https://pubmed.ncbi.nlm.nih.gov/10557283/)
[Ono K, et al, Anti-amyloidogenic activity of EGCG (2003)](https://pubmed.ncbi.nlm.nih.gov/12871651/)
[Lorenzen J, et al, Alpha-synuclein aggregation (2014)](https://pubmed.ncbi.nlm.nih.gov/25307057/)
[Kalfon L, et al, EGCG and tau protein phosphorylation (2007)](https://pubmed.ncbi.nlm.nih.gov/17434756/)
[Ehrnhoefer DE, et al, EGCG and mutant huntingtin (2008)](https://pubmed.ncbi.nlm.nih.gov/18693120/)
[Lin MT, Beal MF, Mitochondrial dysfunction in neurodegenerative diseases (2006)](https://pubmed.ncbi.nlm.nih.gov/17081979/)
[Ni HM, et al, Mitochondrial quality control in neurodegeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/23124840/)
[Piantadosi CA, et al, PGC-1alpha and mitochondrial biogenesis (2011)](https://pubmed.ncbi.nlm.nih.gov/21441412/)
[Youle RJ, Narendra DP, Mechanisms of mitophagy (2011)](https://pubmed.ncbi.nlm.nih.gov/21170055/)
[Green DR, Kroemer G, Cell biology of apoptosis (2005)](https://pubmed.ncbi.nlm.nih.gov/16237011/)
[Dauer W, Przedborski S, Parkinson's disease: mechanisms (2003)](https://pubmed.ncbi.nlm.nih.gov/14585457/)
[Guo S, et al, Tea catechins in Parkinson's disease models (2015)](https://pubmed.ncbi.nlm.nih.gov/26051180/)
[Youdim MB, et al, MAO-B inhibitors in Parkinson's disease (2000)](https://pubmed.ncbi.nlm.nih.gov/10863906/)
[Conway KA, et al, Acceleration of oligomerization by EGCG (2000)](https://pubmed.ncbi.nlm.nih.gov/11062067/)
[Li Q, et al, L-theanine and EGCG combination therapy (2013)](https://pubmed.ncbi.nlm.nih.gov/23991068/)
[Reznichenko L, et al, Green tea polyphenol EGCG in Alzheimer's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16597584/)
[Kelleher SL, et al, Tea polyphenols and cognitive function (2020)](https://pubmed.ncbi.nlm.nih.gov/31841149/)
[Rezai-Zadeh K, et al, Amyloid-beta clearance by EGCG (2008)](https://pubmed.ncbi.nlm.nih.gov/19010212/)
[Wani WY, et al, Tau pathology and EGCG (2018)](https://pubmed.ncbi.nlm.nih.gov/29226558/)
[Song J, et al, Synaptic protection by EGCG (2010)](https://pubmed.ncbi.nlm.nih.gov/20346877/)
[Li R, et al, Green tea and Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26430775/)
[Chen D, et al, Motor function improvement by EGCG (2012)](https://pubmed.ncbi.nlm.nih.gov/22027031/)
[Zhang F, et al, Neuroinflammation in PD models (2013)](https://pubmed.ncbi.nlm.nih.gov/23149440/)
[Koh SH, et al, EGCG in ALS models (2006)](https://pubmed.ncbi.nlm.nih.gov/16026675/)
[Sontag EM, et al, Huntington's disease and EGCG (2014)](https://pubmed.ncbi.nlm.nih.gov/25655960/)
[Shah ZA, et al, Bioavailability of tea polyphenols (2020)](https://pubmed.ncbi.nlm.nih.gov/32057962/)
[Manach C, et al, Polyphenol metabolism (1999)](https://pubmed.ncbi.nlm.nih.gov/10544256/)
[Pardridge WM, Blood-brain barrier delivery (2007)](https://pubmed.ncbi.nlm.nih.gov/17349688/)
[Ramadani M, et al, Enhanced delivery of EGCG (2019)](https://pubmed.ncbi.nlm.nih.gov/31360162/)
[Ide K, et al, Green tea and cognitive function (2019)](https://pubmed.ncbi.nlm.nih.gov/31108662/)
ClinicalTrials.gov, Tea polyphenol clinical trials (2024)
[Bedirli A, et al, Safety of EGCG in clinical trials (2009)](https://pubmed.ncbi.nlm.nih.gov/19228861/)
[Lambert JD, et al, Drug interactions with tea polyphenols (2007)](https://pubmed.ncbi.nlm.nih.gov/17627251/)
[Cheng D, et al, Green tea in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33199288/)
[Sola P, et al, Research gaps in tea polyphenols (2018)](https://pubmed.ncbi.nlm.nih.gov/30541665/)
[Farkhondeh T, et al, Epigenetic effects of EGCG (2020)](https://pubmed.ncbi.nlm.nih.gov/31944456/)
[Nunpait P, et al, Tea polyphenols in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34152482/)Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
- [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
- [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data